March 4, 2021 10:32 AM EST

Galapagos posts a safety win for filgotinib, but is it too little, too late?; Bio-Techne inks $320M molecular diagnostics buyout

John Carroll

Editor & Founder

Kyle Blankenship

Once a promising $725 million play in immunology, Gilead’s big bet on filgotinib effectively disintegrated in December when the drugmaker reworked its partnership with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Galapagos posts a safety win for filgotinib, but is it too little, too late?; Bio-Techne inks $320M molecular diagnostics buyout

John Carroll

Editor & Founder

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Gala­pa­gos posts a safe­ty win for fil­go­tinib, but is it too lit­tle, too late?; Bio-Techne inks $320M mol­e­c­u­lar di­ag­nos­tics buy­out

Editor & Founder

Sign up to read this article for free.

more like this

Galapagos posts a safety win for filgotinib, but is it too little, too late?; Bio-Techne inks $320M molecular diagnostics buyout